Latest post

Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”

“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.

back of the eye diseases, science community,

Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME

In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).

science community

A strategic focus for Oxurion: researching and developing non-VEGF pathways

Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.